Mesoblast plunges as FDA orders additional trial of Ryoncil

Mesoblast plunges as FDA orders additional trial of Ryoncil

Shares in Mesoblast (ASX: MSB) were down 40 per cent this morning after the company was ordered to conduct additional tests on its graft versus host disease (GvHD) treatment remestemcel-L.

After receiving the backing of the Oncologic Drugs Advisory Committee in August, the company today told shareholders the US Food and Drugs Administration (FDA) recommended at least one additional study be completed.

The FDA is looking for more evidence that remestemcel-L, marketed as "Ryoncil", is effective at treating GvHD before it approves the drug.

Mesoblast says it will urgently request a meeting with the FDA within the next 30 days to discuss a potential accelerated approval with a post-approval condition for an additional study.

MSB managing director Joanne Kurtzberg says the request was made as there are currently no approved treatments for GvHD, a life-threatening disease for children under 12.

"The Phase 4 trial results showed that remestemcel-L provides a meaningful treatment for children with SR-aGVHD who have a very dismal prognosis," says Kurtzberg.

"I look forward to having this much-needed therapy available to our patients."

The FDA also identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product's biologic activity.

Shares in Mesoblast are down 35.43 per cent at 11.53am AEST.

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

New report reveals 68 per cent of businesses are vulnerable to a cybersecurity attack

Partner Content
36 per cent of employees fear their organisation is at risk of financial losse...
SAI Global
Advertisement

Related Stories

Smartgroup shares plunge as suitor lowers takeover offer

Smartgroup shares plunge as suitor lowers takeover offer

Shares in Smartgroup (ASX: SIQ) have fallen back to where they were...

APA gets look in at AusNet for $9.96 billion takeover offer

APA gets look in at AusNet for $9.96 billion takeover offer

AusNet Services (ASX: AST) has today granted due diligence access t...

Victorian retail to reopen a week earlier, milestone set for scrapping masks and capacity limits

Victorian retail to reopen a week earlier, milestone set for scrapping masks and capacity limits

With Victoria poised to hit its 80 per cent double dose vaccination...

Go1 founders win Brisbane Young Entrepreneur of the Year Award after decade-long wait

Go1 founders win Brisbane Young Entrepreneur of the Year Award after decade-long wait

After their business became a unicorn amidst the ongoing expansion ...